Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Dec 11;10:596937. doi: 10.3389/fonc.2020.596937

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Kang, Zhang, Chen, Zhong, Xu, Su, Zhou, Tu, Wang, Xu, Yang, Chen, Wu, Zhang, Shao, Wu and Yang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Therapeutic response to next-generation ALK TKIs in post-crizotinib patients. (A) Swimmer plot demonstrating the post-crizotinib treatment history in 63 NSCLC patients. The asterisk represents ongoing treatment with the last follow-up on November 30, 2019. Kaplan-Meier curve of PFS (B) or OS (C) in 63 next-generation ALK TKI-treated NSCLC patients in strata of different ALK fusions. When multiple next-generation ALK TKIs were used after crizotinib, the ALK TKI that immediately followed crizotinib treatment was included for the analysis. The OS was calculated from the date of initiation of crizotinib treatment to death resulting from any causes or was censored at the last follow-up. BH-adjusted p values of the log-rank test were reported for pairwise comparisons.